Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Jan;62(1):4–9. doi: 10.1136/ard.62.1.4

Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

P Ranganathan 1, S Eisen 1, W Yokoyama 1, H McLeod 1
PMCID: PMC1754300  PMID: 12480661

Full Text

The Full Text of this article is available as a PDF (138.8 KB).

Figure 1 .

Figure 1

Open in a new tab

Putative targets for MTX pharmacogenetic analysis (shown in italics).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón G. S., Tracy I. C., Blackburn W. D., Jr Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 1989 Jun;32(6):671–676. doi: 10.1002/anr.1780320603. [DOI] [PubMed] [Google Scholar]
  2. Andersen P. A., West S. G., O'Dell J. R., Via C. S., Claypool R. G., Kotzin B. L. Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med. 1985 Oct;103(4):489–496. doi: 10.7326/0003-4819-103-4-489. [DOI] [PubMed] [Google Scholar]
  3. Anderson J. J., Wells G., Verhoeven A. C., Felson D. T. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000 Jan;43(1):22–29. doi: 10.1002/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  4. Angelis-Stoforidis P., Vajda F. J., Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999 May-Jun;17(3):313–320. [PubMed] [Google Scholar]
  5. Banerjee D., Schweitzer B. I., Volkenandt M., Li M. X., Waltham M., Mineishi S., Zhao S. C., Bertino J. R. Transfection with a cDNA encoding a Ser31 or Ser34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance. Gene. 1994 Feb 25;139(2):269–274. doi: 10.1016/0378-1119(94)90768-4. [DOI] [PubMed] [Google Scholar]
  6. Bannwarth B., Péhourcq F., Schaeverbeke T., Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996 Mar;30(3):194–210. doi: 10.2165/00003088-199630030-00002. [DOI] [PubMed] [Google Scholar]
  7. Barnes M. J., Estlin E. J., Taylor G. A., Aherne G. W., Hardcastle A., McGuire J. J., Calvete J. A., Lunec J., Pearson A. D., Newell D. R. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Clin Cancer Res. 1999 Sep;5(9):2548–2558. [PubMed] [Google Scholar]
  8. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  9. Bleyer W. A. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer. 1978 Jan;41(1):36–51. doi: 10.1002/1097-0142(197801)41:1<36::aid-cncr2820410108>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  10. Boiardi L., Macchioni P., Meliconi R., Pulsatelli L., Facchini A., Salvarani C. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol. 1999 Jul-Aug;17(4):419–425. [PubMed] [Google Scholar]
  11. Brown C. A., McKinney K. Q., Young K. B., Norton H. J. The C677T methylenetetrahydrofolate reductase polymorphism influences the homocysteine-lowering effect of hormone replacement therapy. Mol Genet Metab. 1999 May;67(1):43–48. doi: 10.1006/mgme.1999.2847. [DOI] [PubMed] [Google Scholar]
  12. Buchbinder R., Hall S., Sambrook P. N., Champion G. D., Harkness A., Lewis D., Littlejohn G. O., Miller M. H., Ryan P. F. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993 Apr;20(4):639–644. [PubMed] [Google Scholar]
  13. Carson C. W., Cannon G. W., Egger M. J., Ward J. R., Clegg D. O. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987 Feb;16(3):186–195. doi: 10.1016/0049-0172(87)90021-7. [DOI] [PubMed] [Google Scholar]
  14. Chabner B. A., Allegra C. J., Curt G. A., Clendeninn N. J., Baram J., Koizumi S., Drake J. C., Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest. 1985 Sep;76(3):907–912. doi: 10.1172/JCI112088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chen J., Giovannucci E., Kelsey K., Rimm E. B., Stampfer M. J., Colditz G. A., Spiegelman D., Willett W. C., Hunter D. J. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996 Nov 1;56(21):4862–4864. [PubMed] [Google Scholar]
  16. Chen Z., Karaplis A. C., Ackerman S. L., Pogribny I. P., Melnyk S., Lussier-Cacan S., Chen M. F., Pai A., John S. W., Smith R. S. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet. 2001 Mar 1;10(5):433–443. doi: 10.1093/hmg/10.5.433. [DOI] [PubMed] [Google Scholar]
  17. Chiang P. K., Gordon R. K., Tal J., Zeng G. C., Doctor B. P., Pardhasaradhi K., McCann P. P. S-Adenosylmethionine and methylation. FASEB J. 1996 Mar;10(4):471–480. [PubMed] [Google Scholar]
  18. Ercikan-Abali E. A., Mineishi S., Tong Y., Nakahara S., Waltham M. C., Banerjee D., Chen W., Sadelain M., Bertino J. R. Active site-directed double mutants of dihydrofolate reductase. Cancer Res. 1996 Sep 15;56(18):4142–4145. [PubMed] [Google Scholar]
  19. Evans W. E., Relling M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 Oct 15;286(5439):487–491. doi: 10.1126/science.286.5439.487. [DOI] [PubMed] [Google Scholar]
  20. Frosst P., Blom H. J., Milos R., Goyette P., Sheppard C. A., Matthews R. G., Boers G. J., den Heijer M., Kluijtmans L. A., van den Heuvel L. P. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 May;10(1):111–113. doi: 10.1038/ng0595-111. [DOI] [PubMed] [Google Scholar]
  21. GUBNER R., AUGUST S., GINSBERG V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951 Feb;221(2):176–182. [PubMed] [Google Scholar]
  22. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol. 1980 Jan;17(1):105–110. [PubMed] [Google Scholar]
  23. Galpin A. J., Schuetz J. D., Masson E., Yanishevski Y., Synold T. W., Barredo J. C., Pui C. H., Relling M. V., Evans W. E. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol. 1997 Jul;52(1):155–163. doi: 10.1124/mol.52.1.155. [DOI] [PubMed] [Google Scholar]
  24. Groenendal H., Rampen F. H. Methotrexate and trimethoprim-sulphamethoxazole--a potentially hazardous combination. Clin Exp Dermatol. 1990 Sep;15(5):358–360. doi: 10.1111/j.1365-2230.1990.tb02113.x. [DOI] [PubMed] [Google Scholar]
  25. Gutierrez-Ureña S., Molina J. F., García C. O., Cuéllar M. L., Espinoza L. R. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 1996 Feb;39(2):272–276. doi: 10.1002/art.1780390214. [DOI] [PubMed] [Google Scholar]
  26. Haagsma C. J., Blom H. J., van Riel P. L., van't Hof M. A., Giesendorf B. A., van Oppenraaij-Emmerzaal D., van de Putte L. B. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Feb;58(2):79–84. doi: 10.1136/ard.58.2.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Halla J. T., Hardin J. G. Underrecognized postdosing reactions to methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1994 Jul;21(7):1224–1226. [PubMed] [Google Scholar]
  28. Henderson E. S., Adamson R. H., Oliverio V. T. The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965 Aug;25(7):1018–1024. [PubMed] [Google Scholar]
  29. Hooijberg J. H., Broxterman H. J., Kool M., Assaraf Y. G., Peters G. J., Noordhuis P., Scheper R. J., Borst P., Pinedo H. M., Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532–2535. [PubMed] [Google Scholar]
  30. Kang S. S., Zhou J., Wong P. W., Kowalisyn J., Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988 Oct;43(4):414–421. [PMC free article] [PubMed] [Google Scholar]
  31. Kerstens P. J., Boerbooms A. M., Jeurissen M. E., Fast J. H., Assmann K. J., van de Putte L. B. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol. 1992 Jun;19(6):867–871. [PubMed] [Google Scholar]
  32. Kluijtmans L. A., Kastelein J. J., Lindemans J., Boers G. H., Heil S. G., Bruschke A. V., Jukema J. W., van den Heuvel L. P., Trijbels F. J., Boerma G. J. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1997 Oct 21;96(8):2573–2577. doi: 10.1161/01.cir.96.8.2573. [DOI] [PubMed] [Google Scholar]
  33. Kremer J. M., Alarcón G. S., Lightfoot R. W., Jr, Willkens R. F., Furst D. E., Williams H. J., Dent P. B., Weinblatt M. E. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994 Mar;37(3):316–328. doi: 10.1002/art.1780370304. [DOI] [PubMed] [Google Scholar]
  34. Kremer J. M., Galivan J., Streckfuss A., Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum. 1986 Jul;29(7):832–835. doi: 10.1002/art.1780290703. [DOI] [PubMed] [Google Scholar]
  35. Kremer J. M. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1999 Aug;29(1):14–26. doi: 10.1016/s0049-0172(99)80034-1. [DOI] [PubMed] [Google Scholar]
  36. Kremer J. M., Phelps C. T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. Arthritis Rheum. 1992 Feb;35(2):138–145. doi: 10.1002/art.1780350203. [DOI] [PubMed] [Google Scholar]
  37. Kremer J. M. Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann Intern Med. 2001 Apr 17;134(8):695–706. doi: 10.7326/0003-4819-134-8-200104170-00013. [DOI] [PubMed] [Google Scholar]
  38. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  39. Llorente L., Richaud-Patin Y., Díaz-Borjón A., Alvarado de la Barrera C., Jakez-Ocampo J., de la Fuente H., Gonzalez-Amaro R., Diaz-Jouanen E. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine. 2000 Jan;67(1):30–39. [PubMed] [Google Scholar]
  40. Matherly L. H., Taub J. W. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leuk Lymphoma. 1996 May;21(5-6):359–368. doi: 10.3109/10428199609093433. [DOI] [PubMed] [Google Scholar]
  41. McKendry R. J., Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993 Nov;20(11):1850–1856. [PubMed] [Google Scholar]
  42. McLeod H. L., Evans W. E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol. 2001;41:101–121. doi: 10.1146/annurev.pharmtox.41.1.101. [DOI] [PubMed] [Google Scholar]
  43. Morgan S. L., Baggott J. E., Vaughn W. H., Young P. K., Austin J. V., Krumdieck C. L., Alarcón G. S. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):9–18. doi: 10.1002/art.1780330102. [DOI] [PubMed] [Google Scholar]
  44. Ou C. Y., Stevenson R. E., Brown V. K., Schwartz C. E., Allen W. P., Khoury M. J., Rozen R., Oakley G. P., Jr, Adams M. J., Jr 5,10 Methylenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet. 1996 Jun 28;63(4):610–614. doi: 10.1002/(SICI)1096-8628(19960628)63:4<610::AID-AJMG15>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  45. Pincus T., Callahan L. F., Sale W. G., Brooks A. L., Payne L. E., Vaughn W. K. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984 Aug;27(8):864–872. doi: 10.1002/art.1780270805. [DOI] [PubMed] [Google Scholar]
  46. Prashker M. J., Meenan R. F. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity. Arthritis Rheum. 1995 Mar;38(3):318–325. doi: 10.1002/art.1780380305. [DOI] [PubMed] [Google Scholar]
  47. Pugner K. M., Scott D. I., Holmes J. W., Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000 Apr;29(5):305–320. doi: 10.1016/s0049-0172(00)80017-7. [DOI] [PubMed] [Google Scholar]
  48. Ribbens C., Andre B., Jaspar J. M., Kaye O., Kaiser M. J., De Groote D., Malaise M. G. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol. 2000 Apr;27(4):888–893. [PubMed] [Google Scholar]
  49. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis. 1996;19(5):589–594. doi: 10.1007/BF01799831. [DOI] [PubMed] [Google Scholar]
  50. Rudwaleit M., Yin Z., Siegert S., Grolms M., Radbruch A., Braun J., Sieper J. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis. 2000 Apr;59(4):311–314. doi: 10.1136/ard.59.4.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Seitz M., Dayer J. M. Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment. Rheumatology (Oxford) 2000 Jun;39(6):637–645. doi: 10.1093/rheumatology/39.6.637. [DOI] [PubMed] [Google Scholar]
  52. Skibola C. F., Smith M. T., Kane E., Roman E., Rollinson S., Cartwright R. A., Morgan G. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810–12815. doi: 10.1073/pnas.96.22.12810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999 Nov 22;159(21):2542–2550. doi: 10.1001/archinte.159.21.2542. [DOI] [PubMed] [Google Scholar]
  54. Szeto D. W., Cheng Y. C., Rosowsky A., Yu C. S., Modest E. J., Piper J. R., Temple C., Jr, Elliott R. D., Rose J. D., Montgomery J. A. Human thymidylate synthetase--III. Effects of methotrexate and folate analogs. Biochem Pharmacol. 1979 Sep 1;28(17):2633–2637. doi: 10.1016/0006-2952(79)90039-x. [DOI] [PubMed] [Google Scholar]
  55. Thompson R. N., Watts C., Edelman J., Esdaile J., Russell A. S. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol. 1984 Dec;11(6):760–763. [PubMed] [Google Scholar]
  56. Tonstad S., Refsum H., Ose L., Ueland P. M. The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. J Pediatr. 1998 Feb;132(2):365–368. doi: 10.1016/s0022-3476(98)70465-2. [DOI] [PubMed] [Google Scholar]
  57. Ueland P. M. Pharmacological and biochemical aspects of S-adenosylhomocysteine and S-adenosylhomocysteine hydrolase. Pharmacol Rev. 1982 Sep;34(3):223–253. [PubMed] [Google Scholar]
  58. Ulrich C. M., Kampman E., Bigler J., Schwartz S. M., Chen C., Bostick R., Fosdick L., Beresford S. A., Yasui Y., Potter J. D. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomarkers Prev. 1999 Aug;8(8):659–668. [PubMed] [Google Scholar]
  59. Ulrich C. M., Yasui Y., Storb R., Schubert M. M., Wagner J. L., Bigler J., Ariail K. S., Keener C. L., Li S., Liu H. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001 Jul 1;98(1):231–234. doi: 10.1182/blood.v98.1.231. [DOI] [PubMed] [Google Scholar]
  60. Urano Wako, Taniguchi Atsuo, Yamanaka Hisashi, Tanaka Eiichi, Nakajima Hiroshi, Matsuda Yuko, Akama Hideto, Kitamura Yutaka, Kamatani Naoyuki. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002 Apr;12(3):183–190. doi: 10.1097/00008571-200204000-00002. [DOI] [PubMed] [Google Scholar]
  61. Vilaseca M. A., Monrós E., Artuch R., Colomé C., Farré C., Valls C., Cardo E., Pineda M. Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C-->T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol. 2000;4(6):269–277. doi: 10.1053/ejpn.2000.0379. [DOI] [PubMed] [Google Scholar]
  62. Wallace C. A., Sherry D. D. A practical approach to avoidance of methotrexate toxicity. J Rheumatol. 1995 Jun;22(6):1009–1012. [PubMed] [Google Scholar]
  63. Weinblatt M. E., Coblyn J. S., Fox D. A., Fraser P. A., Holdsworth D. E., Glass D. N., Trentham D. E. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985 Mar 28;312(13):818–822. doi: 10.1056/NEJM198503283121303. [DOI] [PubMed] [Google Scholar]
  64. Weisberg A., Winegrad S. Relation between crossbridge structure and actomyosin ATPase activity in rat heart. Circ Res. 1998 Jul 13;83(1):60–72. doi: 10.1161/01.res.83.1.60. [DOI] [PubMed] [Google Scholar]
  65. Wernick R., Smith D. L. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum. 1989 Jun;32(6):770–775. doi: 10.1002/anr.1780320616. [DOI] [PubMed] [Google Scholar]
  66. West S. G. Methotrexate hepatotoxicity. Rheum Dis Clin North Am. 1997 Nov;23(4):883–915. doi: 10.1016/s0889-857x(05)70365-3. [DOI] [PubMed] [Google Scholar]
  67. Williams H. J., Willkens R. F., Samuelson C. O., Jr, Alarcón G. S., Guttadauria M., Yarboro C., Polisson R. P., Weiner S. R., Luggen M. E., Billingsley L. M. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1985 Jul;28(7):721–730. doi: 10.1002/art.1780280702. [DOI] [PubMed] [Google Scholar]
  68. Yasui K., Kowa H., Nakaso K., Takeshima T., Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology. 2000 Aug 8;55(3):437–440. doi: 10.1212/wnl.55.3.437. [DOI] [PubMed] [Google Scholar]
  69. Zonneveld I. M., Bakker W. K., Dijkstra P. F., Bos J. D., van Soesbergen R. M., Dinant H. J. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol. 1996 Feb;132(2):184–187. [PubMed] [Google Scholar]
  70. van Ede A. E., Laan R. F., Blom H. J., De Abreu R. A., van de Putte L. B. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998 Apr;27(5):277–292. doi: 10.1016/s0049-0172(98)80049-8. [DOI] [PubMed] [Google Scholar]
  71. van Ede A. E., Laan R. F., Blom H. J., Huizinga T. W., Haagsma C. J., Giesendorf B. A., de Boo T. M., van de Putte L. B. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 2001 Nov;44(11):2525–2530. doi: 10.1002/1529-0131(200111)44:11<2525::aid-art432>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  72. van der Put N. M., Gabreëls F., Stevens E. M., Smeitink J. A., Trijbels F. J., Eskes T. K., van den Heuvel L. P., Blom H. J. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet. 1998 May;62(5):1044–1051. doi: 10.1086/301825. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES